Best Readout Podcasts (2024)

1
303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc 31:45

2h ago31:45

31:45

We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field. Here's where you can subscribe to our biotech newsletter, The Readout…

1
302: Vertex's big deal, biotech's red numbers, & an industry history lesson 24:48

7d ago24:48

24:48

How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss a multibillion-dollar deal from Vertex Pharmaceuticals with sweeping implications and a lengthy backstory. We also explain why gas prices are weighing on biotech, and make a…

1
Five For Friday - March 22th Readout 2:47

27d ago2:47

2:47

Dustin Lanier reviews the curated procurement and public sector news of the week in audio, and also with links at https://www.linkedin.com/in/dustin-lanier-cppo/

1
Q&A 1:18:34

4d ago1:18:34

1:18:34

6276_20240410_PMBy Clifford H. Readout Jr.

1
How is Your Spiritual Stamina 49:51

4d ago49:51

49:51

6275_20240407_PMBy John Readout

1
Thou Preparest 37:30

4d ago37:30

37:30

6274_20240407_AMBy Peggy Readout

1
The Past, Present, and Future of Longevity w/ Joe Betts-LaCroix Alex Colville 38:19

8d ago38:19

38:19

In this episode, Omri Amirav-Drory (NFX), Joe Betts-LaCroix (Retro Bio), and Alex Colville (Age1) discuss the history, recent progress, and hurdles in the longevity industry, including the evaluation of potential founders and business risks. The discussion further encompasses the global fundraising potential and societal impact of the longevity sec…

1
NASPO Acquisition Support Services Category Re-Award - Did You Know? 2:27

9d ago2:27

2:27

Dustin summarizes the re-award of Civic Initiatives in the NASPO Acquisition Support Services Category which happened in early April, in terms of how it is used, and partners in the effort.

1
Don’t be a Nervous Nilly / Leave the Nets 38:45

11d ago38:45

38:45

6273_20240403_PM_PBy Brookelyn Readout / Stephen Readout

1
He is Risen-The Power and Promise of the Resurrection 34:43

11d ago34:43

34:43

6272_20240331_PM_PBy John Readout

1
A Call or Condemnation 33:20

11d ago33:20

33:20

6271_20240331_AM_PBy Philip Barrett

1
Garden of Surrender 32:59

11d ago32:59

32:59

6270_20240327_PM_PBy Jacy Pulford

1
Affinity with Ahab 1:03:39

11d ago1:03:39

1:03:39

6269_2024324_PM_PBy Philip Barrett

1
Thy Rod and Thy Staff Comfort Me 38:48

11d ago38:48

38:48

6268_2024324_AM_PBy Peggy Readout

1
301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise 31:37

14d ago31:37

31:37

Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space. We also discuss the latest news in the life sciences, including the end of the Amylyx ALS saga, another use case for GLP-1s, and a hurdle in Verve’s gene editing plans. Here’s w…

1
300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech 34:21

21d ago34:21

34:21

Our colleague Sarah Owermohle joins us to explain the Supreme Court case that could have dramatic effects on access to medication abortion — and the development of new medicines. We also discuss the latest news in the life sciences, including a contrarian take on a new obesity treatment, a congressional effort to ban Chinese biotech companies, and …

1
Celebrating #ProcurementMonth 2:14

22d ago2:14

2:14

Dustin writes on the value of Procurement Month in highlighting the work of procurement professionals for their work, as well as helping market the profession for the next generation of job seekers.

1
Build the Boat 38:15

25d ago38:15

38:15

6267_2024320_PM_PBy Jacy Pulford

1
The Frustration of His Promises 41:20

25d ago41:20

41:20

6266_2024317_PM_PBy Jeremiah Rivera

1
Thou Art With Me 41:36

25d ago41:36

41:36

6265_2024317_AM_PBy Peggy Readout

1
299: Live! From the STAT Breakthrough Summit East 33:54

28d ago33:54

33:54

Recorded live from from the STAT Breakthrough Summit East in New York City, we discuss some event highlights, including words from CRISPR pioneer Feng Zhang and Regeneron Pharmaceuticals head scientist George Yancopoulos. We also discuss the latest news in the life sciences, including a twist in the GLP-1 story, the cost of gene therapy, and, of co…

1
The NFX Podcast w/ Alex Babin of HerculesAI 35:09

29d ago35:09

35:09

Hercules builds high-quality, enterprise-grade AI solutions based on data extraction, transformation, and verification, while integrating with enterprise systems and tools for maintenance and monitoring. Join NFX general partner James Currier and HerculesAI CEO Alex Babin talk about the latest breakthroughs in the AI space of enterprise companies. …

1
Q & A 58:44

1M ago58:44

58:44

6264_2024313_PM_PBy Clifford H. Readout Jr.

1
Purged, Profitable and Prepared 39:15

1M ago39:15

39:15

6262_2024310_AM_PBy Philip Barrett

1
Take Every Thought Captive 29:43

1M ago29:43

29:43

6261_2024306_PM_PBy Stephen Readout

1
How is Your Backbone_Courageous Surrender 55:45

1M ago55:45

55:45

6260_2024303_PM_PBy John Readout

1
Which Vessel 35:32

1M ago35:32

35:32

6259_2024303_AM_PBy Phil Barrett

1
Five For Friday - March 15th Readout 3:27

1M ago3:27

3:27

Dustin Lanier reviews the curated procurement and public sector news of the week in audio, and also with links at https://www.linkedin.com/in/dustin-lanier-cppo/

1
298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard 35:21

1M ago35:21

35:21

Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver…

1
Five For Friday - March 8th Readout 4:58

1M ago4:58

4:58

Dustin Lanier reviews the curated procurement and public sector news of the week in audio, and also with links at https://www.linkedin.com/in/dustin-lanier-cppo/

1
297: VC turmoil, GLP-1 competition, & the war on recovery 27:11

1M ago27:11

27:11

For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots o…

1
Hidden in the Earth 41:39

2M ago41:39

41:39

6258_2020228_PM_PBy Jacy Pulford

1
How is Your Backbone_Joshua 48:16

2M ago48:16

48:16

6254_2020218_PM_PBy John Readout

1
296: Legal insider trading, booming biotech stocks, & the next GLP-1 24:21

2M ago24:21

24:21

We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it's such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research. Here's where you can subscribe to our biotech newsletter, The Readout. And here'…

1
A Leap Year Retrospective: Where We Were, and Where We Are 6:51

2M ago6:51

6:51

Dustin takes the opportunity of Leap Day to look back where we were on the last Leap Pay - February 29, 2020. Observations inlcude both public procurement in general and the changes of Civic Initiatives as a service provider.